美德纳Moderna Inc. (MRNA) 2022年年度报告「NASDAQ」.pdf

1、2022a n n u a l r e p o r tA letter from our CEOPipelineAccelerating our progressBuilding our teamResponsibilityLeadershipAwards and recognitionFinancialsTable of ContentsTable of contents05 A letter from our CEO15 Pipeline18 Accelerating our progress19 Building our team21 Responsibility24 Leadershi

2、p25 Awards and recognition26 FinancialsFranceGermanySwitzerlandItalyUnited KingdomSpainUnited StatesCanadaSouth Korea AustraliaJapanPolandTaiwanHong KongSingaporeSwedenNetherlands17 locations across North America,Europe and Asia Pacific where Moderna employees liveand work03moderna 2022annual report

3、moderna 2022annual report03A letter from our CEOPipelineAccelerating our progressBuilding our teamResponsibilityLeadershipAwards and recognitionFinancialsTable of ContentsModerna by the numbers50%women in our workforceAll figures as of December 31,2022.2020202120222544482020202120221325362010 foundi

4、ng yearDevelopment programs in active clinical trialsDevelopment programs41%of executives are women(up from 39%last year)8years in a row as a Science top employer5Medical areas offocusInfectious Diseases Immuno-Oncology Rare DiseasesCardiovascular DiseasesAutoimmune Diseases3,900+team members worldw

5、ide(up from 2,700 last year)Cambridge,MAheadquarters04moderna 2022annual reportA letter from our CEOPipelineAccelerating our progressBuilding our teamResponsibilityLeadershipAwards and recognitionFinancialsTable of ContentsSince I shared my annual letter on January 3,the Moderna team has continued t

6、o make significant progress at speed.As we work to advance our new mission,I am pleased to provide a few updates:Progressing our RSV vaccine programOn January 17,we announced that our investigational mRNA vaccine targeting respiratory syncytial virus(RSV)met primary efficacy endpoints in our Conquer